GSA Capital Partners LLP Has $490,000 Holdings in Lyell Immunopharma, Inc. (NASDAQ:LYEL)

GSA Capital Partners LLP raised its holdings in shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) by 1,285.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 354,815 shares of the company’s stock after buying an additional 329,205 shares during the quarter. GSA Capital Partners LLP’s holdings in Lyell Immunopharma were worth $490,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of LYEL. ProShare Advisors LLC raised its stake in shares of Lyell Immunopharma by 9.3% in the first quarter. ProShare Advisors LLC now owns 48,986 shares of the company’s stock valued at $109,000 after purchasing an additional 4,170 shares in the last quarter. Acadian Asset Management LLC acquired a new position in Lyell Immunopharma during the first quarter worth $173,000. Price T Rowe Associates Inc. MD raised its stake in Lyell Immunopharma by 1.4% during the first quarter. Price T Rowe Associates Inc. MD now owns 6,731,477 shares of the company’s stock worth $15,013,000 after acquiring an additional 92,594 shares in the last quarter. Caxton Associates LP raised its stake in Lyell Immunopharma by 359.1% during the first quarter. Caxton Associates LP now owns 174,657 shares of the company’s stock worth $389,000 after acquiring an additional 136,611 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. acquired a new position in Lyell Immunopharma during the first quarter worth $64,000. 66.05% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

LYEL has been the subject of several recent analyst reports. HC Wainwright reiterated a “neutral” rating and set a $1.00 price objective on shares of Lyell Immunopharma in a research note on Tuesday, November 12th. Bank of America lowered Lyell Immunopharma from a “buy” rating to an “underperform” rating and dropped their price objective for the stock from $6.00 to $1.00 in a research note on Wednesday, October 30th.

Lyell Immunopharma Stock Performance

Shares of LYEL stock opened at $1.11 on Wednesday. The stock’s fifty day moving average is $1.21 and its 200-day moving average is $1.65. The stock has a market capitalization of $309.94 million, a PE ratio of -1.41 and a beta of -0.47. Lyell Immunopharma, Inc. has a 52 week low of $0.85 and a 52 week high of $3.26.

Lyell Immunopharma (NASDAQ:LYEL) last announced its earnings results on Thursday, November 7th. The company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.03. The company had revenue of $0.03 million for the quarter. Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%. As a group, analysts forecast that Lyell Immunopharma, Inc. will post -0.8 earnings per share for the current fiscal year.

Lyell Immunopharma Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.